Skip to main content
. Author manuscript; available in PMC: 2022 Aug 19.
Published in final edited form as: Cancer Res. 2022 Aug 16;82(16):2838–2847. doi: 10.1158/0008-5472.CAN-22-0554

Figure 3. Tumor mutation profiling of bronchoalveolar lavage fluid in at risk controls identifies field cancerization.

Figure 3.

(A) Mean VAF% (y-axis, log10 scale) for mutations detected in lung cancer patients compared to risk-matched controls for BAL cfDNA (p<0.001) and plasma cfDNA (p=0.002) by the tumor naïve calling approach (Supplemental Table 8). Box plots depict median values, 25-75% interquartile range, and minimal and maximal values. The number of variants represented in the scatter plots are denoted in the x-axis labels. Blue = BAL cfDNA. Red = plasma. P-values are displayed above the plot.

(B) Fraction of cancer patients and controls with driver mutations detected in BAL (blue) or plasma cfDNA (red). NS = not significant.

(C) Oncoprint of lung cancer driver genes in 27 lung cancer cases and 21 risk-matched controls for BAL cfDNA profiles (Supplemental Table 8). Tumor DNA results are shown for cancer patients. Each column denotes one patient and each row a driver mutation. For mutations found in tumors, BAL cfDNA mutations are only shown if they are identical. Clinical characteristics (tumor histology, tumor stage according to AJCC VIII guidelines, smoking status, and age in years) are displayed. NSCLC = Non-small cell lung cancer.